The biopharmaceutical company shared clinical findings related to its investigational therapy at a major respiratory congress.
Savara presented data on molgramostim at the European Respiratory Society International Congress held in September. The presentation covered clinical findings from ongoing research on the investigational therapy.
Further details regarding the data or its implications were not immediately available.
Priya covers listed equities and corporate earnings, reading quarterly results and guidance for what they signal about sector health and forward valuations.
More from Priya Anand →
